Pawełczyk Anna, Nowak Rafał, Gazecka Monika, Jelińska Anna, Zaprutko Lucjusz, Zmora Paweł
Department of Organic Chemistry, Pharmaceutical Faculty, Poznan University of Medical Sciences, 60-780 Poznan, Poland.
Department of Molecular Virology, Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland.
Pathogens. 2023 Jul 18;12(7):951. doi: 10.3390/pathogens12070951.
The COVID-19 pandemic provoked a global health crisis and highlighted the need for new therapeutic strategies. In this study, we explore the potential of the molecular consortia of cannabidiol (CBD) and non-steroidal anti-inflammatory drugs (NSAIDs) as novel antiviral dual-target agents against SARS-CoV-2/COVID-19. CBD is a natural compound with a wide range of therapeutic activities, including antiviral and anti-inflammatory properties, while NSAIDs are commonly used to mitigate the symptoms of viral infections. Chemical modifications of CBD with NSAIDs were performed to obtain dual-target agents with enhanced activity against SARS-CoV-2. The synthesised compounds were characterised using spectroscopic techniques. The biological activity of three molecular consortia (CBD-ibuprofen, CBD-ketoprofen, and CBD-naproxen) was evaluated in cell lines transduced with vesicular stomatitis virus-based pseudotypes bearing the SARS-CoV-1 or SARS-CoV-2 spike proteins or infected with influenza virus A/Puerto Rico/8/34. The results showed that some CBD-NSAID molecular consortia have superior antiviral activity against SARS-CoV-1 and SARS-CoV-2, but not against the influenza A virus. This may suggest a potential therapeutic role for these compounds in the treatment of emerging coronavirus infections. Further studies are needed to investigate the efficacy of these compounds in vivo, and their potential use in clinical settings. Our findings provide a promising new approach to combatting current and future viral emergencies.
新冠疫情引发了全球健康危机，并凸显了对新治疗策略的需求。在本研究中，我们探索了大麻二酚（CBD）与非甾体抗炎药（NSAIDs）的分子组合作为针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）/新冠病毒的新型抗病毒双靶点药物的潜力。CBD是一种具有广泛治疗活性的天然化合物，包括抗病毒和抗炎特性，而NSAIDs通常用于减轻病毒感染的症状。对CBD与NSAIDs进行化学修饰以获得对SARS-CoV-2活性增强的双靶点药物。使用光谱技术对合成的化合物进行表征。在转导了携带SARS-CoV-1或SARS-CoV-2刺突蛋白的基于水疱性口炎病毒的假型病毒或感染了甲型流感病毒A/波多黎各/8/34的细胞系中评估了三种分子组合（CBD-布洛芬、CBD-酮洛芬和CBD-萘普生）的生物活性。结果表明，一些CBD-NSAIDs分子组合对SARS-CoV-1和SARS-CoV-2具有优异的抗病毒活性，但对甲型流感病毒没有。这可能表明这些化合物在治疗新出现的冠状病毒感染中具有潜在的治疗作用。需要进一步研究来调查这些化合物在体内的疗效及其在临床环境中的潜在用途。我们的研究结果为应对当前和未来的病毒紧急情况提供了一种有前景的新方法。
